Table 1.
Patient Characteristics
| Patient Characteristics | Tigecycline ± Standard of Care (n = 21) | Standard of Care (n = 69) |
P Value |
|---|---|---|---|
| Demographics | |||
| Age (years, median, interquartile range) | 75 (52–81) | 77 (58–85) | .24 |
| Male, n (%) | 9 (42.9) | 27 (39.1) | .76 |
| Patient Factors | |||
| Previous CDI, n (%) | 5 (23.8) | 7 (10.1) | .14 |
| Body mass index >30, n (%) | 7 (33.3) | 23 (33.3) | 1.0 |
| Active malignancy, n (%) | 5 (23.8) | 18 (26.1) | .83 |
| Bone marrow transplant, n (%) | 1 (4.8) | 1 (1.5) | .41 |
| Solid organ transplant, n (%) | 3 (14.3) | 4 (5.8) | .35 |
| Inflammatory bowel disease, n (%) | 0 (0) | 9 (13.0) | .08 |
| Glucocorticoid use, n (%) | 3 (14.3) | 11 (15.9) | 1.0 |
| Admission Information | |||
| Service, n (%) | .10 | ||
| Medicine | 20 (95.2) | 54 (78.3) | |
| Other | 1 (4.8) | 15 (21.7) | |
| Intensive care unit admission, n (%) | 14 (66.7) | 54 (78.3) | .38 |
| Intensive care unit admission for CDI, n (%) | 13 (61.9) | 52 (75.4) | .23 |
| Mechanical ventilation, n (%) | 7 (33.3) | 13 (18.8) | .23 |
| Pressor therapy, n (%) | 8 (38.1) | 26 (37.7) | .97 |
| White Blood Cell Count, Range (%) | |||
| <4 | 3 (14.3) | 6 (8.7) | .43 |
| 4–11 | Reference group | Reference group | |
| >11 | 16 (76.2) | 47 (68.1) | .48 |
| Serum creatinine >1.2 mg/dL, n (%) | 13 (61.9) | 34 (49.3) | .31 |
| Modified ARC Score | .75 | ||
| 0–3 | 10 (47.6) | 28 (40.6) | |
| 4–7 | 11 (52.4) | 40 (58.0) | |
| >8 | 0 (0) | 1 (1.4) | |
| Concurrent infection, n (%) | 12 (57.1) | 25 (36.2) | .13 |
| Bloodstream infection | 4 (19.0) | 6 (8.7) | .23 |
| Intra-abdominal infection | 4 (19.0) | 1 (1.4) | .01 |
| Urinary tract infection | 4 (19.0) | 11 (15.9) 10 | .74 |
| CAP/HCAP/HAP | 1 (4.7) | (14.5) | .45 |
| Ventilator-associated pneumonia | 1 (4.7) | 3 (4.4) | 1.0 |
| Complicated skin and soft tissue infection | 2 (9.5) | 1 (1.4) | .13 |
| Receipt of non-CDI antibiotics within 1 week of CDI diagnosis, n (%) | 16 (76.2) | 55 (79.7) | .73 |
| Infectious diseases consult, n (%) | 21 (100) | 17 (24.6) | <.001 |
| Gastroenterology consult, n (%) | 8 (38.1) | 14 (20.3) | .10 |
| Endoscopy, n (%) | 3 (14.3) | 5 (7.2) | .38 |
| Surgery consult or primary surgical service, n (%) | 16 (76.1) | 23 (33.3) | <.001 |
| Treatment, n (%) | |||
| Vancomycin, oral administration | 21 (100) | 59 (85.5) | .11 |
| Vancomycin, rectal administration | 10 (47.6) | 13 (18.8) | .02 |
| Metronidazole | 21 (100) | 66 (95.6) | 1.0 |
| Intravenous immunoglobulin | 3 (14.3) | 0 (0) | .01 |
| Cholestyramine | 2 (9.5) | 4 (5.8) | .62 |
Abbreviations: ARC, age, renal disease, and cancer; CAP, community-acquired pneumonia; CDI, Clostridium difficile infection; HAP hospital-acquired pneumonia; HCAP, healthcare- associated pneumonia.